Kleger group

 

• Defining acute pancreatic injury (API)
• Structure-function alteration of the pancreas after direct and remote trauma and related longterm consequences
• Building a unique biobank of patient-derived organoids to enable precision oncology, personalized drug screening, and predictive therapeutic profiling
• Advancing organoid-based platforms using bioprinting and microfluidics to model complex pancreatic tissue architecture, co-culture interactions, and dynamic microenvironments
• Deciphering genomically unstable pancreatic cancer by leveraging cutting-edge mouse and human models to uncover novel, actionable therapeutic targets
• Differentiating human pluripotent stem cells into pancreatic lineages to study development, tissue homeostasis, and disease mechanisms in conditions like familial pancreatic cancer, hereditary pancreatitis, diabetes, and cystic fibrosis